Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

Breast cancer is the most common cancer in women and the second leading cause of cancer-related deaths after lung cancer.

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) and published in The Journal of Internal Medicine shows that, in survivors of breast ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.